The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes.
Maren K. Levin
No relevant relationships to disclose
Kai Wang
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Roman Yelensky
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Ying Cao
No relevant relationships to disclose
Corinne Ramos
Employment or Leadership Position - Theranostics Health
Glenn D. Hoke
Employment or Leadership Position - Theranostics Health
Stock Ownership - Theranostics Health
John E. Pippen
No relevant relationships to disclose
Joanne Lorraine Blum
No relevant relationships to disclose
Barry Don Brooks
No relevant relationships to disclose
Gary A. Palmer
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Norma Alonzo Palma
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Sohail Balasubramanian
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Jeffrey S. Ross
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Research Funding - Foundation Medicine
Joyce O'Shaughnessy
No relevant relationships to disclose